Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

October 17, 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Press Releases

October 17, 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Press Releases

October 17, 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Press Releases

October 17, 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Press Releases

October 17, 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Press Releases

October 17, 2017

Press Releases

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Subscribe to email alert

Navigation

Contact Us